NCT02086032

Brief Summary

Investigators have found that sleeping disorder is an important problem in menopausal women. There have been papers reporting the effect of hormonal therapy on sleeping, but fews have reported the effect of different progestogens on sleeping quality. There is a need for more in-depth study and more conclusive evidence about the progestins which have the most beneficial effects on sleeping disorders in menopausal women. This study is going to collect the data from newly identified menopausal patients who are eligible for continuous estrogen-progestogen therapy for their climacteric treatment. The affects of the therapy will be monitored for 3 months.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2014

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2014

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

March 1, 2014

Completed
12 days until next milestone

First Posted

Study publicly available on registry

March 13, 2014

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2015

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2015

Completed
Last Updated

May 31, 2017

Status Verified

May 1, 2017

Enrollment Period

1.4 years

First QC Date

March 1, 2014

Last Update Submit

May 28, 2017

Conditions

Keywords

Sleeping qualitymenopauseclimactericprogestindydrogesteronemicronized progesterone

Outcome Measures

Primary Outcomes (1)

  • Improving of sleeping quality (assessed by the PSQI score)

    from March 2014 up to 15 months

Secondary Outcomes (2)

  • The side effects comparing the 2 arms.

    from March 2014 up to 15 months

  • The climacteric symptoms comparing the 2 arms.

    from March 2014 up to 15 months

Study Arms (2)

micronized progesterone

EXPERIMENTAL

1 mg 17 beta-estradiol plus 100 mg micronized progesterone taken orally once a day for 3 months.

Drug: 1mg 17 beta-estradiolDrug: micronized progesterone

dydrogesterone

EXPERIMENTAL

1mg 17 beta-estradiol plus 10 mg dydrogesterone taken orally once a day for 3 months.

Drug: 1mg 17 beta-estradiolDrug: Dydrogesterone

Interventions

Comparing sleeping quality between micronized progesterone and dydrogesterone users.

Also known as: Estrogen
dydrogesteronemicronized progesterone

Comparing sleeping quality between micronised progesterone and dydrogesterone users.

Also known as: Duphaston
dydrogesterone

Comparing sleeping quality between micronised progesterone and dydrogesterone users

Also known as: Utrogestan
micronized progesterone

Eligibility Criteria

Age40 Years - 65 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • new menopausal patients at Maharaj Nakorn Chiang Mai Hospital
  • suitable for estrogen plus progesterone treatment

You may not qualify if:

  • contraindication for hormone replacement therapy
  • recently used sleep enhancing medicine
  • recently used psychotic medicine

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Obstetrics and Gynecology department, Faculty of Medicine, Chiang Mai University

Muang, Chiang Mai, 50200, Thailand

Location

Related Publications (1)

  • Leeangkoonsathian E, Pantasri T, Chaovisitseree S, Morakot N. The effect of different progestogens on sleep in postmenopausal women: a randomized trial. Gynecol Endocrinol. 2017 Dec;33(12):933-936. doi: 10.1080/09513590.2017.1333094. Epub 2017 Jun 13.

MeSH Terms

Interventions

EstradiolEstrogensDydrogesteroneProgesteroneUtrogestan

Intervention Hierarchy (Ancestors)

EstrenesEstranesSteroidsFused-Ring CompoundsPolycyclic CompoundsEstradiol CongenersGonadal Steroid HormonesGonadal HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsPhysiological Effects of DrugsPharmacologic ActionsChemical Actions and UsesPregnadienesPregnanesPregnenedionesPregnenesCorpus Luteum HormonesProgesterone Congeners

Study Officials

  • Tawiwan Pantasri, MD

    Faculty of Medicine, Chiang Mai University, Thailand

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

March 1, 2014

First Posted

March 13, 2014

Study Start

January 1, 2014

Primary Completion

June 1, 2015

Study Completion

July 1, 2015

Last Updated

May 31, 2017

Record last verified: 2017-05

Locations